2017年-ASCO免疫治疗.pptxVIP

2017 ASCO CORE SLIDES;目录;Increased CD73 and Reduced IFNγ Signature Expression May Contribute to Low Response Rates to Anti-PD-1(L1) Therapies in EGFR-Mutant NSCLC;EGFR突变亚组的患者从抗PD-1/PD-L1治疗中获益偏少;研究背景：腺苷旁路;研究目的与设计;EGFR突变的NSCLC患者高表达CD73和低表达γ-干扰素印记;CD73高表达是NSCLC预后不良的指标;CD73通过作用腺苷旁路改变肿瘤细胞和免疫细胞的功能;CD73通过作用腺苷旁路改变肿瘤细胞和免疫细胞的功能;EGFR突变细胞系显著上调CD73表达;CD73表达可被EGF诱导产生，在应用EGFR-TKI后降低;CD73高表达和PD-L1蛋白低表达相关;假说：CD73的过表达在EGFRm+肿瘤中营造了免疫抑制的微环境;结论;Updated Safety and Clinical Activity of Durvalumab Monotherapy in Previously Treated Patients with Stage IIIB/IV NSCLC;研究背景;研究设计;基线特征;研究结果：药物相关不良反应;特别关注的药物相关不良反应;研究结果：ORR;研究结果：出现应答时间、应答持续时间;研究结果：DCR、肿瘤体积变化;研究结果：OS;研究结果：PFS;研究结果：后线治疗与一线治疗OS对比 ;结论;Durvalumab的其他相关研究;Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy.;研究背景与目的;研究方法;入组患者临床特征;两组患者发生irAE的严重程度及特点;再次治疗组发生irAE的严重程度及特点;再次治疗组发生irAE的严重程度及特点;PFS OS;结论;Immune related adverse events (irAE) with platinum chemotherapy (CT) with durvalumab (D) ± tremelimumab (T): CCTG IND226.;背景;背景;研究方法;研究方法;结果;结果;结果;总结;Neoadjuvant nivolumab in early-stage, resectable non-small cell lung cancers;Nivolumab新辅助治疗原理;Nivolumab新辅助治疗模式;研究终点;IB-IIIA期 NSCLC患者（n=22） ;基线水平;主要终点;2周期nivolumab后影像学变化;2周期nivolumab后影像学变化;临床随访;多标记物免疫荧光染色显示治疗后CD8+ T细胞浸润;相关研究背景;突变负荷与新抗原;TCRseq: CDR3区域深度测序以分析整个TCR及T细胞克隆状态;T细胞对主要突变相关新抗原的特殊作用在nivolumab新辅助治疗后扩张;结论;Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032;研??背景;Presented By Matthew Hellmann at 2017 ASCO Annual Meeting;Presented By Matthew Hellmann at 2017 ASCO Annual Meeting;Presented By Matthew Hellmann at 2017 ASCO Annual Meeting;Presented By Matthew Hellmann at 2017 ASCO Annual Meeting;Presented By Matthew Hellmann at 2017 ASCO Annual Meeting;Presented By Matthew Hellmann at 2017 ASCO Annual Meeting;Presented By Matthew Hellmann at 2017 ASCO Annual Meeting;Presented By Matthew Hellmann at 2017 ASCO Annual Meeting;合并 -